Alzheimer's Disease: New Insights Into Mechanisms and Emerging Treatments
A comprehensive 2025 review maps AD's intertwined pathological pathways and evaluates the full landscape of emerging therapies.
Summary
This 2025 review in the European Journal of Medical Research systematically examines Alzheimer's disease (AD) pathogenesis and therapeutic advances. The authors detail how amyloid-beta plaques, tau neurofibrillary tangles, neuroinflammation, autophagy failure, mitochondrial dysfunction, and gut-brain axis dysregulation collectively drive neurodegeneration over a silent 15–25 year preclinical window. Genetic risk factors including APOE ε4 and TREM2 variants amplify disease susceptibility. The review critically evaluates emerging biomarkers—blood-based, CSF, and neuroimaging—for earlier detection, and assesses pharmacological strategies such as anti-amyloid immunotherapies, tau-targeting agents, and anti-inflammatory treatments alongside non-pharmacological interventions including diet, exercise, and cognitive training. The authors conclude that multimodal, personalized approaches targeting multiple pathological processes simultaneously represent the most promising path forward.
Detailed Summary
Alzheimer's disease (AD) afflicts approximately 50 million people globally and is projected to reach 152 million by 2050, imposing an estimated $1 trillion annual economic burden. Despite over a century of research, no disease-modifying therapy exists, making a clear-eyed synthesis of pathogenic mechanisms and treatment progress critically important for researchers and clinicians alike.
The review opens by establishing AD's canonical hallmarks: extracellular amyloid-beta (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. Aβ peptides—particularly the more toxic Aβ42 isoform—are generated from amyloid precursor protein (APP) by sequential β- and γ-secretase cleavage (via BACE1 and presenilin 1/2). Mutations in APP, presenilin genes, or APOE4 shift processing toward aggregation-prone peptides. Tau pathology proceeds via dysregulated GSK-3β and CDK5 kinases that hyperphosphorylate tau, destabilizing microtubules, impairing axonal transport, and forming insoluble NFTs. Crucially, Aβ amplifies tau pathology by activating calpain-mediated cleavage of p35 to p25, prolonging CDK5 activity, while defective TREM2 signaling impairs microglial clearance of tau aggregates.
Synaptic dysfunction sits at the convergence of these pathologies. Aβ oligomers disrupt intracellular calcium homeostasis and impair endoplasmic reticulum Ca²⁺ storage, while pathological tau disrupts synaptic protein function and axonal transport. Both glutamatergic (NMDA receptor-mediated excitotoxicity) and cholinergic systems (depleted acetylcholine, altered choline acetyltransferase and AChE activity) are compromised, explaining why current symptomatic drugs target these neurotransmitter systems.
Beyond these classical mechanisms, the review highlights several underappreciated drivers. Neuroinflammation is framed as both consequence and cause: microglia initially restrict Aβ plaques via pattern recognition receptors (TLR2, RAGE) but transition to a dysfunctional, chronically activated state that perpetuates cytokine dysregulation (IL-1β, TNF-α), reduces neurotrophic support (BDNF, IGF), compromises the blood-brain barrier, and accelerates tau phosphorylation. Gut-brain axis dysbiosis in AD patients triggers immune activation, promotes nitric oxide production via NMDA receptor pathways, and allows gut-derived LPS and bacterial amyloids to amplify neuroinflammation. Autophagy dysfunction leads to accumulation of immature autophagosomes and failure to clear Aβ and tau aggregates, while mitochondrial dysfunction contributes to neuronal energy failure. These mechanisms interact in self-reinforcing cycles.
On the therapeutic front, the review critically appraises recently FDA-approved anti-amyloid immunotherapies (lecanemab, donanemab), acknowledging limited clinical efficacy and significant adverse effects including amyloid-related imaging abnormalities (ARIA). Tau-targeting strategies, anti-inflammatory agents, neurotransmitter modulators, autophagy enhancers, mitochondrial protectants, and gut microbiome interventions (probiotics such as Bifidobacterium and Lactobacillus casei) are all evaluated. Non-pharmacological strategies—dietary patterns, aerobic exercise, sleep optimization, and cognitive training—are presented as meaningful adjuncts. The authors advocate for personalized, multimodal regimens that combine early biomarker-guided detection with simultaneous targeting of multiple pathological nodes.
Key Findings
- AD pathogenesis involves at least six interacting mechanisms: Aβ plaques, tau tangles, neuroinflammation, autophagy failure, mitochondrial dysfunction, and gut dysbiosis.
- APOE ε4 and TREM2 variants modulate Aβ processing and microglial clearance, significantly amplifying disease risk and progression.
- Chronic microglial overactivation drives a self-sustaining neuroinflammatory cycle that compromises the BBB and accelerates tau hyperphosphorylation.
- Approved anti-amyloid immunotherapies show limited clinical benefit and carry meaningful ARIA risks, underscoring unmet need for better therapies.
- Multimodal interventions combining early biomarker detection with simultaneous targeting of multiple pathways are proposed as the most promising strategy.
Methodology
This is a comprehensive narrative review synthesizing evidence from molecular studies, animal models, clinical trials, and post-mortem neuropathological data published through mid-2025. No systematic search protocol or PRISMA methodology is explicitly described. The authors are affiliated with neurology and emergency medicine departments at two Chinese university hospitals.
Study Limitations
As a narrative review without a registered systematic protocol, it is subject to selection bias in the literature cited and does not provide quantitative effect-size synthesis. The review covers an exceptionally broad scope, which limits the depth of critical appraisal for any individual mechanism or therapy. Many of the promising interventions discussed (autophagy enhancers, gut microbiome therapies, mitochondrial protectants) remain in preclinical or early-phase clinical stages with unproven efficacy in humans.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.